spacer
home > > autumn 2003 > new approaches to developing cancer drugs
PUBLICATIONS


New Approaches to Developing Cancer Drugs

The latest statistics make alarming reading: in the developed world one in three people will suffer from cancer and one in four will die from the disease. Due to an ageing population the worldwide incidence of cancer is predicted to double from 10 to 20 million by 2020 (WHO). Traditional approaches to cancer treatment rely on a combination of surgery, radiotherapy and chemotherapy. Current cancer drugs, which are mostly lethal for cells (cytotoxic), either affect DNA synthesis and the process of cell division or they react chemically with DNA to cause chromosomal damage.

These drugs have major limitations as they damage all proliferating cells and therefore produce considerable side effects. Drug resistance is another serious problem. Hence there is a major unmet need for more systematic but innovative and effective therapies for cancer treatment, especially for targeting early stages of the disease or later stage metastatic disease.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Gijsbertus J Pronk PhD, Senior Director, US Business Development at atugen AG

Gijsbertus J Pronk, PhD, is Senior Director in charge of US business development for atugen AG, Germany. Bert joined atugen, USA Inc in 2000 as Director of Research having formerly been Senior Scientist for Target Development with Chiron Corporation. Previously he held various research posts including a post-doctoral assignment in the laboratory of Dr Lewis T Williams at the Cardio-Vascular Research Institute (CVRI) at UC-San Francisco, where he studied programmed cell death (apoptosis).

spacer
Gijsbertus J Pronk
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus

1st September 2020 – Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and Hovione Technology, a pharmaceutical specialist in the development of innovative pulmonary device technology, today unveiled a collaboration supporting Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix, a formulation of Budesonide Formoterol for Asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement